A

Electrochemiluminescence (ECL) assays significantly enhanced prediction of the timing of type 1 diabetes onset among autoantibody-positive TrialNet participants, outperforming models that relied on traditional radioimmunoassays alone [Fouts et al., 2016, PMID 27456836].